4-traders (press release) Nexavar in combination with gemcitabine /cisplatin is not recommended in patients with squamous cell lung cancer. The safety and effectiveness of Nexavar has not been established in patients with non-small cell lung cancer. Nexavar can prolong the QT ... and more »
MarketWatch Following this, one-third of the normal dosage of ifosfamide was administered. Historical data for Eli Lilly's Gemzar(R) (generic is Elan's Gemcitabine IV), at the time of the writing of the study report, with the same type of patients, gave a median ...
NASDAQ Finally, OncoGenex Pharmaceuticals, Inc. (OGXI) has initiated the Rainier clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen (OGX-427) in combination with ABRAXANE and gemcitabine in patients ... and more »
4-traders (press release) PharmaEngine, Inc. (TWO:4162) announced today that the British Journal of Cancer has published the paper "A Multinational Phase 2 Study of Nano...
HispanicBusiness.com ... randomized, placebo-controlled Phase 2 trial evaluating apatorsen (OGX-427) in combination with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic ... and more »
Curetoday.com (press release) A third arm of the study that added gemcitabine to one of the regimens also showed no difference in survival. "We have made huge progress in the adjuvant treatment of breast cancer but have reached a point where the addition of other drugs used in a ... and more »
StreetInsider.com (subscription) Rainier will randomize approximately 130 patients to receive either apatorsen or placebo in combination with ABRAXANE and gemcitabine therapy. The primary objective of the trial is overall survival (OS), with additional analyses to evaluate progression ... and more »
7thSpace Interactive (press release) Gemcitabine was administered at 1000 mg/m2 as protracted infusion (100 min) on day 1, and oxaliplatin at the dose of 100 mg/m2 on day 2 in a 2 hour infusion. Cycles were repeated every two weeks. Results: We observed an overall response rate of 37% ...
MarketWatch NEW YORK, NY, Aug 22, 2013 (Marketwired via COMTEX) -- While Eli Lilly's cancer fighting drug Gemzar ( gemcitabine ) has been on the market since the late 1990s, its success with cancer duly noted, other big pharmaceutical companies are combining their ...
